Key Stats for Regeneron Stock
- Price change for Regeneron stock: -12%
- $REGN Stock Price as of May. 18: $697
- 52-Week High: $821
- $REGN Stock Price Target: $867
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Regeneron (REGN) stock dropped sharply on Monday after the company disclosed that its experimental combination of melanoma drugs failed a key late-stage trial.
- The combination of fianlimab and cemiplimab — sold as Libtayo — did not reach statistical significance in improving progression-free survival compared to Merck’s Keytruda in patients with advanced melanoma.
- In plain terms, the drug showed a roughly five-month improvement over Keytruda, but the difference wasn’t large enough to be considered statistically meaningful.
- That distinction matters enormously to regulators and investors.
At least ten brokerages cut their price targets on Regeneron stock following the news. BMO analyst Evan Seigerman summed up the mood bluntly, noting that back-to-back pipeline misses increase pressure on the company’s development over the next 12 to 18 months.
This isn’t Regeneron’s first recent setback.
The company has also faced regulatory delays for a pre-filled syringe version of its eye drug Eylea, and suffered a late-stage failure of its lung drug itepekimab last year.
See analysts’ growth forecasts and price targets for Regeneron stock (It’s free) >>>
What the Market Is Telling Us About Regeneron Stock
The reaction to Regeneron stock is severe but somewhat understandable.
Melanoma was supposed to be a major commercial opportunity for the fianlimab combination. Missing the primary endpoint compared with the market-leading Keytruda eliminates the near-term revenue story.
Regeneron does have a separate trial comparing fianlimab against Bristol Myers Squibb’s Opdualag. However, at least two analysts say they have low confidence in a positive result there, either.
To be fair, Regeneron’s core business remains strong.
- Q1 revenue grew 19% year-over-year to $3.6 billion.
- Dupixent hit $4.9 billion in quarterly sales, up 31% on a constant currency basis.
- The company also announced a new $3 billion share buyback program.
But for now, Regeneron stock is being judged on its pipeline, not its fundamentals.
Separately, the company announced a partnership with Parabilis Medicines with up to $2.2 billion in potential milestone payments — a small positive amid the noise.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Regeneron Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
